The concept of nucleic acid-based therapeutics is not a new one. For a long time it has been thought that molecules similar to those that make up our genetic structure would make effective therapeutics. It is an idea whose time has come.
There are six types of nucleic acid-based therapeutics that have been proposed. Some have made it to market, others are still in development, and some have been put on the back burner due to technical difficulties. The six technologies examined in this study are:
- Ribonucleic acid inhibition (RNAi)
- Gene therapy
- Nucleoside analogs
- Ribozymes, and
This report focuses on the application of nucleic acid-based therapeutics to the prevention and treatment of various diseases and disorders:
- Rheumatoid arthritis
- Diabetes (Types I and II)
- Cardiovascular disease (hypertesion, Coronary artery disease, and congestive heart failure)
- Autoimmune diseases (psoriasis, lupus erythematosus, psoriatic arthritis, and scleroderma)
- Neurological Diseases (peripheral neuropathies, Alzheimer’s disease, epilepsy, Parkinson’s disease, multiple sclerosis, severe traumatic brain injury, and spinal cord injury)
- Viral Diseases, and
- Miscellaneous conditions
The report examines the options that these new therapeutics present, the progress that is being made in these fields, and the motivations for broader pharmaceutical industry involvement in these markets. The major market effects of nucleic acid-based therapeutics are seen as having the potential to significantly impact the seven major world healthcare markets over the next ten years. The trends selected in conjunction with the growing interest in preventive medicine alone, and gene vaccines specifically, and the application to current health priorities present the most informative picture of advances in this field and the markets that result.
Market analysis for this report considers the various applications of nucleic acid-based therapeutics rather than the markets for specific products in the seven major world healthcare markets:
- United States
- United Kingdom
- Italy, and
The analysis presented in this report is based on data from a combination of company, government, industry, institutional, and private sources. It includes information from extensive literature reviews, as well as in-depth interviews and discussions with experts in the field, including medicinal chemists, experts in genetics and genomics, medical professionals, research scientists, business development managers, and marketing managers.